Fund Details
Tata India Pharma & HealthCare Fund Direct Growth
| Risk | High |
|---|---|
| Min SIP Amount | ₹500 |
| Expense Ratio | 1.19% |
| NAV | ₹16.26 (22 Jan 2021) |
|---|---|
| Fund Started | 28 Dec 2015 |
| Fund Size | ₹419 Cr |
Returns
Comparison
1. 3Y Returns are higher than the category average returns
1. Asset under management(AUM) is less than 500 Crs. Watch expense ratio when AUM is very low
2. Risk-adjusted returns are lower compared to the category
3. 1Y Returns are lower than the category average returns
Top Holdings
| Name | Sector | Instrument | % Assets |
|---|---|---|---|
| Dr. Reddy's Laboratories Ltd. | Healthcare | Equity | 13.4% |
| Sun Pharmaceutical Inds. Ltd. | Healthcare | Equity | 9.8% |
| Cipla Ltd. | Healthcare | Equity | 9.0% |
| Divi's Laboratories Ltd. | Healthcare | Equity | 8.5% |
| Narayana Hrudayalaya Ltd. | Healthcare | Equity | 7.0% |
| Ipca Laboratories Ltd. | Healthcare | Equity | 6.5% |
| Alkem Laboratories Ltd. | Healthcare | Equity | 6.2% |
| Lupin Ltd. | Healthcare | Equity | 4.7% |
| Procter & Gamble Health Ltd. | Healthcare | Equity | 4.2% |
| Apollo Hospitals Enterprise Ltd. | Healthcare | Equity | 4.1% |
Fund Managers
Tata India Pharma & HealthCare Fund Direct Growth Details
Tata India Pharma & HealthCare Fund Direct Growth is a Equity Mutual Fund Scheme launched by Tata Mutual Fund. This scheme was made available to investors on 28 Dec 2015. Rupesh Patel, Sonam Udasi is the Current Fund Manager of Tata India Pharma & HealthCare Fund Direct Growth fund.The fund currently has an Asset Under Management(AUM) of ₹419 Cr and the Latest NAV as of 22 Jan 2021 is ₹16.26.
The Tata India Pharma & HealthCare Fund Direct Growth is rated High risk. Minimum SIP Investment is set to 500. Minimum Lumpsum Investment is 5000. For units in excess of 12% of the investment,1% will be charged for redemption within 365 Days.
Investment Objective
The scheme seeks long term capital appreciation by investing atleast 80% of it's net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.
Tax Implications
Returns are taxed at 15%, if you redeem before one year. After 1 year, you are required to pay LTCG tax of 10% on returns of Rs 1 lakh+ in a financial year.
